Metagenomi Therapeutics, Inc. announced a corporate name change to reflect its strategic evolution focused on later-stage preclinical assets leveraging gene-editing capabilities.
The name change aligns with the Company's lead program in hemophilia A and other programs for near-term success.
The Company highlighted key achievements in 2025 and provided insights into anticipated milestones in 2026.
MGX-001 Program Achievements
New preclinical data demonstrated curative FVIII activity in NHPs, informing clinical dose strategy for best-in-class treatment potential.
Secreted Protein Deficiencies
In vivo proof-of-concept for Antithrombin (AT-III) Deficiency signifies MGX-001's potential for additional curative therapies.
Cardiometabolic Programs
Presented APOC3 as a new collaboration target with Ionis Pharmaceuticals, focusing on significant cardiometabolic indications.
- Metagenomi Therapeutics aims to advance its lead programs, including the MGX-001 hemophilia A program, to clinical development.
- Strategic pipeline prioritization reinforces the Company's commitment to curative genetic medicines and strengthens its balance sheet.
- Appointment of Jian Irish, Ph.D., M.B.A., as CEO signifies leadership in accelerating development and capitalizing on proprietary technologies.
The corporate name change and strategic focus underline Metagenomi Therapeutics' dedication to delivering curative genetic medicines and advancing innovative therapies.